The UK, on the basis of a democratic decision, can unilaterally revoke a decision to withdraw from the EU as long as the withdrawal agreement has not entered into force, the Court of Justice of the European Union, announced on 10 December.
GlaxoSmithKline Plc has taken a major step to rebuild its oncology portfolio with the agreed acquisition of Tesaro, Inc for $5.1 billion which has a poly ADP ribose polymerase (PARP) inhibitor on the market for the treatment of patients with ovarian cancer. This drug is Zejula (niraparib).
Novartis has agreed to offer Kymriah (tisagenlecleucel) the cell-based gene therapy, for an undisclosed discount to patients under the age of 25 years following a negotiation with UK authorities, including the National Institute for Health and Care Excellence (NICE). Supplies of Kymriah will be financed through the Cancer Drugs Fund, a special fund for promising treatments, NICE announced on 16 November.
A Chinese scientist’s reported use of the Crispr gene editing tool to alter a gene in two embryos which were implanted into a mother’s womb has created an uproar in the scientific community. The edit was performed when the embryos were just a day old and involved alterations to the CCR5 gene in order to prevent the offspring from contracting HIV. They were reported on YouTube videos, rather in a scientific journal, after twin girls bearing the DNA changes were born.
The Bayer Group plans to reduce its global workforce by 10% over the next three years as it prepares to integrate Monsanto Co into its global operations following its acquisition of the US agrochemical company for $66 billion in June. A significant number of the job losses will be in Germany, Bayer announced on 29 November.
A new precision medicine for patients whose cancers have a specific genetic feature has been approved by the US Food and Drug Administration – the second time the agency has based a decision on a common biomarker rather than the location of a tumour in the body.
The Germany-based biotech company, Adrenomed AG, has raised €24 million in a Series D financing round to secure the clinical development of a new medicine for septic shock, a life-threatening condition that occurs when a person’s blood pressure drops after an infection.
The US Food and Drug Administration has approved a new oral treatment for acute myeloid leukaemia (AML) in adults who are 75 years or older and who have other chronic conditions that may preclude the use of intensive chemotherapy. The drug, Daurismo (glasdegib), is an inhibitor of the Hedgehog pathway which when abnormal, is thought to contribute to the development of cancer stem cells. Daurismo was developed by Pfizer Inc.
The European Commission has cleared Takeda Pharmaceutical Company Ltd’s proposed $62 billion takeover of Shire Plc, subject to its disposal of an investigational drug in Shire’s portfolio for the treatment of inflammatory bowel disease (IBD). The Shire compound overlaps with Entyvio, a drug marketed by Takeda for the same disease.
Takeda has offered to divest the experimental treatment, including the rights to its development, manufacture and marketing to a purchaser that would have an incentive to produce a competitor to Entyvio.
Evotec AG has launched a new drug discovery collaboration involving artificial intelligence – this time to identify small molecules to treat rare hereditary metabolic diseases. The partner is Immuneering Corp of Cambridge, Massachusetts which is 51% controlled by Teva Pharmaceutical Industries Ltd.
Immuneering applies AI and other advanced algorithms to data derived from high throughput screening. The goal is to identify molecular structures that could form the basis of new medicines.